These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Relative Bioavailability of a Single 4-mg Dose of Somatropin Administered by Subcutaneous Injection or by Needle-free Device and Coadministered With the Growth Hormone Inhibitor Octreotide Acetate in Healthy Adult Subjects. Brimhall DB; Petri N; D'Angelo P Clin Ther; 2018 May; 40(5):741-751. PubMed ID: 29699852 [TBL] [Abstract][Full Text] [Related]
6. Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers. Lewis AL; Jordan F; Patel T; Jeffery K; King G; Savage M; Shalet S; Illum L J Clin Endocrinol Metab; 2015 Nov; 100(11):4364-71. PubMed ID: 26425883 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe. Agersø H; Møller-Pedersen J; Cappi S; Thomann P; Jesussek B; Senderovitz T J Clin Pharmacol; 2002 Nov; 42(11):1262-8. PubMed ID: 12412826 [TBL] [Abstract][Full Text] [Related]
8. A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. Jostel A; Mukherjee A; Alenfall J; Smethurst L; Shalet SM Clin Endocrinol (Oxf); 2005 May; 62(5):623-7. PubMed ID: 15853836 [TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial]. Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Safety Profile of DA-3803, a Proposed Biosimilar of Recombinant Human Chorionic Gonadotropin, in Healthy Subjects. Cha YJ; Kim KA; Oh TY; Park JY BioDrugs; 2015 Jun; 29(3):199-205. PubMed ID: 25998212 [TBL] [Abstract][Full Text] [Related]
11. Plasma growth hormone-binding protein activity, insulin-like growth factor I, and its binding protein levels in patients with Turner's syndrome: effect of short- and long-term recombinant human growth hormone administration. Saggese G; Federico G; Cinquanta L Pediatr Res; 1995 Jan; 37(1):106-11. PubMed ID: 7535419 [TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of Spanish growth hormone deficient children: results of a phase III study. López-Siguero J; Borrás Pérez MV; Balser S; Khan-Boluki J Adv Ther; 2011 Oct; 28(10):879-93. PubMed ID: 21948492 [TBL] [Abstract][Full Text] [Related]
13. Effects of China-made recombinant human growth hormone on the treatment of growth hormone deficiency. Jiang J; Wang W; Sun WX; Wang XM; Ni JH; Chen FS; Wang DF Chin Med Sci J; 2004 Sep; 19(3):225-9. PubMed ID: 15506654 [TBL] [Abstract][Full Text] [Related]
14. 17beta-estradiol regulation of human growth hormone (hGH), insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) axis in hypoestrogenic, hypergonadotropic women. Milewicz T; Krzysiek J; Sztefko K; Radowicki S; Krzyczkowska-Sendrakowska M Endokrynol Pol; 2005; 56(6):876-82. PubMed ID: 16821205 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and Pharmacodynamic Modeling of MOD-4023, a Long-Acting Human Growth Hormone, in Growth Hormone Deficiency Children. Fisher DM; Rosenfeld RG; Jaron-Mendelson M; Amitzi L; Koren R; Hart G Horm Res Paediatr; 2017; 87(5):324-332. PubMed ID: 28399519 [TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896 [TBL] [Abstract][Full Text] [Related]
17. Preclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation. Vlugt-Wensink KD; de Vrueh R; Gresnigt MG; Hoogerbrugge CM; van Buul-Offers SC; de Leede LG; Sterkman LG; Crommelin DJ; Hennink WE; Verrijk R Pharm Res; 2007 Dec; 24(12):2239-48. PubMed ID: 17929148 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191 [TBL] [Abstract][Full Text] [Related]
19. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. Rasmussen MH; Bysted BV; Anderson TW; Klitgaard T; Madsen J J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. Keller A; Wu Z; Kratzsch J; Keller E; Blum WF; Kniess A; Preiss R; Teichert J; Strasburger CJ; Bidlingmaier M Eur J Endocrinol; 2007 Jun; 156(6):647-53. PubMed ID: 17535864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]